Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

116.83 +0.23 (+0.20%)
Official Closing Price Updated: 7:00 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,349,380
Open 116.50
Bid (Size) 113.40 (1)
Ask (Size) 117.72 (2)
Prev. Close 116.60
Today's Range 115.59 - 117.31
52wk Range 89.67 - 121.64
Shares Outstanding 1,750,942,289
Dividend Yield 1.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why ABBOTT LABORATORIES (NYSE:ABT) should be investigated by quality investors.
Is ABBOTT LABORATORIES (NYSE:ABT) a Strong Candidate for Quality Investing? 
Via Chartmill
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
You can take these dividends straight to the bank. 
Via The Motley Fool

Performance

YTD
+6.35%
+6.35%
1 Month
+7.94%
+7.94%
3 Month
+12.93%
+12.93%
6 Month
-1.70%
-1.70%
1 Year
+13.77%
+13.77%

More News

Read More
Medtronic Stock: Growth On Rise of the Cardiovascular Machines
Via MarketBeat
Abbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Abbott's 'Transformative' Move And Answer To Dexcom's Newest Device
Via Investor's Business Daily
Looking Into Abbott Laboratories's Recent Short Interest
Via Benzinga
Abbott Laboratories Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Patchy But Still Bullish
Via Talk Markets
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
Via The Motley Fool
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Via Benzinga
Dexcom's Stelo Device Brings Affordable Continuous Glucose Monitoring To Type 2 Diabetes Patients
Via Benzinga
Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?
Via Investor's Business Daily
This Is Great News for Medtronic, but Is It Time to Buy the Stock?
Via The Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
Via The Motley Fool
Topics Government
Exposures Political
3 Unstoppable Dividend Stocks to Buy Right Now
Via The Motley Fool
Diabetes and Neuro Products Ignite Medtronic’s Q1 Earnings Rally
Via MarketBeat
Exposures Product Safety
Abbott Laboratories, Nu Holdings And More On CNBC's 'Final Trades'
Via Benzinga
Looking for Safe Dividend Income? These 3 Stocks Have Rock-Solid Payouts.
Via The Motley Fool
Abbott Laboratories Stock Could Soar to $143, According to a Wall Street Analyst. Is It a Buy Around $108?
Via The Motley Fool
3 Stocks Retirees Should Absolutely Love
Via The Motley Fool
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
Via FinancialNewsMedia
Chips, Glorious Chips!
Via The Motley Fool
3 Dividend Growth Stocks to Buy Hand Over Fist in August
Via The Motley Fool
Large Cap Biopharma And Healthcare, A Port In A Storm
Via Talk Markets
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.